Tag Archives: Cancer

$ 14 million in grant to support Pacific Island cancer research | Instant News


PICTURE: Pacific Island Partnership for Health Equality Leaders at the Program Steering Committee Meeting held in February 2019 at the University of Guam. (From left) Neal A. Palafox, UHCC; Engelberta …
look more

Credit: University of Guam

The University of Guam and the University of Hawai’i Cancer Center have each been awarded a five-year grant totaling more than $ 14 million to reduce the impact of cancer on the Pacific Islands through cancer research, career training, and community outreach. The collaboration between the two universities, known as the Pacific Island Partnership for Cancer Health Equity (PIPCHE), will be funded by the National Cancer Institute until 31 August 2025.

Funds from PIPCHE are used to support the research infrastructure needed to address significant cancer health disparities in the Pacific.

“PIPCHE has been truly transformational for research here at UOG for this region,” said Rachael Leon Guerrero, Ph.D., RD, principal investigator of the grant and vice-chancellor of research and sponsored programs at the University of Guam. “Prior to PIPCHE, there was very little cancer and health-related research going on that was relevant to the Guam population. Now we have several federal research grants studying cancer, childhood obesity, cardiometabolic health, and dementia.”

PIPCHE is the only NCI-funded Pacific-based partnership addressing cancer disparities in other US-affiliated Hawai’i, Guam and Pacific Island communities, which include the Northern Mariana Islands, American Sāmoa, Federated States of Micronesia, Marshall Islands and Palau . It also provides research training for students and early career scientists while engaging the public in outreach activities to advance knowledge, awareness, behavior change and public health policies in Guam and Hawai’i.

“We are using cancer research as a platform to bring equity and resilience to indigenous Pacific peoples,” said Neal A. Palafox, MD, MPH, UH Cancer Center researcher and principal investigator of the grant at UHCC. “… The investment has brought cancer researchers and scientific leaders native to the Pacific, relevant Pacific-based interventions for addressing cancer disparities, and has increased the capacity for both institutions to understand and achieve cancer health justice in the Pacific.”

The first PIPCHE grant was awarded to the University of Guam and the UH Cancer Center in 2003.Since then, the fund has supported 25 research projects, trained more than 100 underrepresented students and early career scientists, contributed to more than 100 peer-reviewed publications, and , in the last cycle alone, raised more than $ 34 million in additional external funding to explore research questions unique to the Pacific region.

“17 years have been an exciting and eye-opening journey,” said Palafox.

Cancer prevention and control in the Pacific is a joint mission between the UH Cancer Center, the University of Guam, and their collaborators. PIPCHE provides a platform to do more than any agency alone can accomplish.

This partnership effort was directed by Leon Guerrero and Palafox as well as the Dean of the UOG Health Faculty Margaret Hattori-Uchima, Ph.D., RN, and Director of the UH Cancer Center Randall Holcombe, MD, MBA, along with other teams. than 50 investigators and staff at partner institutions.

###

Rejection: AAAS and EurekAlert! is not responsible for the accuracy of news releases posted to EurekAlert! by contributing to the institution or for the use of any information through the EurekAlert system.

.



image source

A $ 14 million award for addressing cancer disparities across the Pacific | Instant News


UH Cancer Center and UOG Team (2018).

That University Hawaii Cancer Center and University of Guam (UOG) has been awarded a total of $ 14 million over five years to reduce the impact of cancer in the Pacific Islands through cancer research, career training, and community outreach. That UH Cancer Center-UOG collaboration, known as the Pacific Island Partnership for Cancer Health Equity (PIPE), funded by the National Cancer Institute (NCI) until 31 August 2025.

Funds from PIPE used to support the research infrastructure needed to address significant cancer health disparities in the Pacific. PIPE is the only one NCIfunded Pacific-based research partnerships that address cancer diversity in societies Hawaii, Guam and WE The Affiliated Pacific Islands, which include the Commonwealth of Northern Mariana, American Samoa, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. It also provides research training for students and early career scientists while engaging the community in outreach activities to advance knowledge, awareness, behavior change and public health policy in Guam and Hawaii.

“Partnerships are negotiated between UOG and UH The Cancer Center uses cancer research as a platform to bring equity and resilience to Indigenous Pacific people. We are working towards reciprocity, transparency and accountability for each partner in all work with our community, ”said Neal A. Palafox, researcher and principal investigator at UH Cancer Center. ”

Palafox adds, “The investment has brought Indigenous Pacific cancer researchers and scientific leaders to the relevant Pacific-based interventions for addressing cancer differences, and has increased the capacity for both institutions to understand and achieve cancer health justice in the Pacific. This partnership has been an exciting and eye-opening journey. ”

First PIPE grant awarded to UH Cancer Center and UOG in 2003. Since then, the fund has supported 25 research projects, trained more than 100 underrepresented students and early career scientists, contributed more than 100 peer-reviewed publications and, in the last cycle alone, earned $ 34 million- plus additional external funding to explore research questions unique to the Pacific region.

For more, go to UH Cancer Center website.

.



image source

Immunophotonics Announces the Appointment of Jonathan Knowles to the Board of Directors | Instant News


BERN, Switzerland, 05 Oct 2020 (GLOBE NEWSWIRE) – Immunophotonics, Inc., a biotech company focused on discovering and developing immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has strengthened its expertise through the appointment of Jonathan Knowles, Ph.D. to the Board of Directors.

“Dr. Knowles has made important contributions in developing and commercializing many drugs in several therapeutic areas. His insights will be invaluable in advancing IP-001 through clinical development and commercialization, ”said Dr. Bobby W. Sandage, Jr., Chair of the Immunophotonics Council. IP-001 is the company’s main asset in clinical development.

Lu Alleruzzo, CEO of Immunophotonics, was honored to welcome the new Board members and commented “I really look forward to working with Dr. Knowles to advance our program, leveraging his strategic, operational and scientific knowledge as we continue to validate the science behind the IP-001 immune modulation properties. “

Dr. Knowles has reached the pinnacle of academic achievement and applied his studies to the pharmaceutical industry with a proven track record of advancing scientific innovation through clinical development and global adoption. In his opinion, “Immunophotonics has a unique and innovative approach to treating serious cancer through immune stimulation. Initial data look very interesting and the drug could potentially help many metastatic cancer patients who are eligible for ablation or radiation therapy. I look forward to interacting more closely with the company’s great scientists in the future. “

About Prof. Dr. Jonathan Knowles, Ph.D.

Dr. Jonathan Knowles has held faculty positions at various first-class institutions, including the University of Oxford, Swiss EPFL, University of Basel, and University of Helsinki. His innate curiosity and determination to apply cutting-edge science to develop effective pharmaceuticals propelled him into leading positions in the pharmaceutical industry, including Research Group President and Member of the Roche Group Executive Committee, Member of the Board of Directors of Genentech and Chugai Pharmaceuticals, and Chair of the Federation’s Research Directors Group. European Pharmaceutical Industry Association (EFPIA). Most recently, he served as Chairman of the Board for Immunocore Ltd. and Adaptimmune Ltd., two major British biotech companies. Dr. Knowles is a visionary who dares to overcome the limitations of existing therapies and has dedicated his talents to developing innovative diagnostics and drugs with healing potential.

About Immunophotonics

Immunophotonics is a privately owned clinical stage biotechnology pioneering the field of Interventional Immuno-OncologyTM. IP-001, the first asset of the company’s intellectual property platform, has the potential to transform routine tumor ablation into systemically active cancer immunotherapy in a variety of solid tumor indications. The company is based in St. Petersburg. Louis, Missouri, USA with subsidiaries in Bern, Switzerland and Tianjin, China.

Contact:
Dr. Theresa Visarius
Vice President of Business Development, Immunophotonics, Inc.
Managing Director, IPS Biopharma AG
[email protected]
www.immunophotonics.com

This press release contains forward-looking statements it may be involves inherent uncertainty and actual results maybe differ materially. Immunophotonics, Inc. is not obligated to update the information, except as required by applicable law.

.



image source

Accord Launches 2 Biosimilar in UK, Expanding Partnership With Henlius | Instant News


In the last 2 weeks, Accord Healthcare said it had launched 2 biosimilar oncology in the UK, including the biosimilar products pegfilgrastim and trastuzumab.

The launch of the biosimilar trastuzumab (Zercepac) Accord was carried out after receiving regulation approval from the European Commission (EC) in July 2020.

EC given marketing authorization to pegfilgrastim Accord (Pelgraz) in September 2018.

Cancer is the leading cause of death in the United Kingdom, Accord described in the press release. Although medical advances have allowed patients with cancer to live longer, the costs of cancer care in Europe have doubled over the past 25 years, reaching an estimated € 103 billion (approximately $ 120 billion).

Apart from these 2 products, the Accord has 2 other biosimilar, including the biosimilar filgrastim (Accofil), which was approved for marketing in Europe in 2015 and is the first biosimilar company to receive European marketing authorization.

Expanding the Zercepac Partnership

Zercepac, which references Genentech’s Herceptin, was developed in collaboration with Shanghai Henlius Biotech.

Most recently, Henlius is based in Shanghai, China announced that it would amend its original agreement with the Accord to allow UK-based companies to have commercialization rights for Zercepac in the United States and Canada.

Initially, 2 companies come in became a licensing agreement for Zercepac in 2018. Under the agreement, the Accord was granted exclusive commercialization rights in 53 countries including the United Kingdom, the European Union, 17 countries in the Middle East and North Africa, and several Commonwealth of Independent States.

Under the amendments, the US Accord would provide Henlius achievement payments which would include a $ 27 million upfront payment, a $ 13 million regulatory compliance payment, and a $ 25 million commercial sales achievement payment for every $ 500 million of cumulative net sales for Zercepac. .

Henlius is also entitled to receive tiered royalty payments of up to 50% of Zercepac’s future net income.

More on Pelgraz

Referring to Neulasta Amgen, Pelgraz has received indications for treating patients with cancer who have febrile neutropenia as a result of undergoing cytotoxic chemotherapy and giving the patient one dose per cycle chemotherapy regime with a self-injecting device that allows the drug to be administered at home.

“Evidence shows that traveling to, and visiting hospitals, is one of the major factors contributing negatively to the quality of life for people living with cancer. Reducing the number of times patients have to visit a clinic or hospital, when they are living with chemotherapy side effects and when their immune system is compromised, should be a priority for patients and their healthcare team, “Professor Hartmut Link, professor of Medicine and external faculty at University Medical Center in Hannover, Germany, word in a statement.

Pelgraz is the second pegfilgrastim biosimilar to receive regulatory authorization.

More on Zercepac

Zercepac is receiving indications for treatment HER2early-positive breast cancer, HER2metastatic-positive and previously untreated breast cancer HER2metastatic -positive gastric cancer.

“We are proud to launch Zercepac in the UK and offer healthcare professionals an additional option of this vital oncology treatment,” said Anup Sidhu, director of Accord’s specialty brands. “This is our first monoclonal antibody launch, reinforcing our commitment to ensuring improved patient access while helping to relieve some of the stress on an overwhelmed healthcare system.”

Zercepac marks the Accords’ first monoclonal antibody product despite having more than 30 oncology treatments available across Europe.

The trastuzumab molecule is currently available in Germany, Portugal and Spain.

In August 2020, Helius received regulatory approval for Zercepac for marketing in China.

.



image source

PM wears pink ribbon to join breast cancer awareness movement – Pakistan | Instant News


Published in October 01, 2020 10:40 p.m.

PM wears pink ribbon to follow breast cancer awareness movement

ISLAMABAD (Dunya News) – Prime Minister Imran Khan Thursday wore a pink ribbon as part of a month-long breast cancer awareness movement that aims to prevent disease through early diagnosis and break lingering taboos.

The Prime Minister’s Office also shared an image showing the prime minister with a pink ribbon pinned to his vest at the initiative of First Lady Samina Arif Alvi to create mass awareness about the disease in the country.

The pink ribbon was presented by President Dr Arif Alvi, who in his letter asked the prime minister to wear it on October 1 or throughout the month, if possible, to give a message to the public to defeat the deadly disease.

The President views that Pakistan has a high prevalence of breast cancer which has been identified as the most common malignancy among Pakistani women, with young girls also being affected now.

“This alarming situation demands our immediate attention to raise awareness about self-examination and early detection to save lives,” said the president, who also informed the prime minister of the First Lady’s awareness efforts to help save thousands of precious lives.

The president said October is International Breast Cancer Awareness Month to help focus attention and support for awareness, and asked the prime minister for support for a noble cause.

.



image source